SEARCH

SEARCH BY CITATION

References

  • 1
    Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 148091.
  • 2
    Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104(Suppl. 1): S135.
  • 3
    Saito YA., Locke GR., Talley NJ., et al. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 281624.
    Direct Link:
  • 4
    Saito YA, Schoenfeld P, Locke GR 3rd. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97: 19105.
  • 5
    Quander C, Morris MC, Bienias JL, Evans DA. Prevalence of irritable bowel syndrome in an older bi-racial population [Abstract 1085]. Am J Gastroenterol 2007; 102: S516.
  • 6
    Locke GR., Clark S., Cerulli A., et al. Work productivity is more impaired in functional gastrintestinal disorders compared to GERD: six-month data from PROGRESS [abstract 1052]. Am J Gastroenterol 2007; 102: S504.
  • 7
    Drossman DA., Chey WD., Panas R., et al. Lubiprostone significantly improves symptom relief rates in adults with irritable bowel syndrome and constipation (IBS-C): data from two, twelve-week, randomized, placebo-controlled, double blind trials [abstract]. Gastroenterology 2007; 132: 639f.
  • 8
    Drossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome – results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther 2009; 29: 32941.
  • 9
    Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000; 95: 9991007.
    Direct Link:
  • 10
    Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998; 43: 40011.
  • 11
    Guo Z, Gill TM, Allore HG. Modeling repeated time-to-event health conditions with discontinuous risk intervals. An example of a longitudinal study of functional disability among older persons. Methods Inf Med 2008; 47: 10716.
  • 12
    Camilleri M, Bharaucha AE, Ueno R, et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 2006; 290: G9427.
  • 13
    Cuppoletti J, Malinowska DH, Tewari KP, et al. SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol 2004; 287: C117883.
  • 14
    Moeser AJ., Nighot PK., Engelke KJ., Ueno R, Blikslager AT. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the CIC-2 chloride channel, lubiprostone. Am J Physiol Gastrointest Liver Physiol 2007; 292: G64756.
  • 15
    Camilleri M, Gorman H. Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 54552.
  • 16
    Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, four-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator in patients with chronic constipation. Am J Gastroenterol 2008; 103: 1707.
    Direct Link:
  • 17
    Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008; 27: 68596.